Skip to main content
SpringerLink
Log in

Estandarización en el diseño y realización de evaluaciones económicas: recomendaciones y guías existentes

  • Chapter
  • First Online:
Evaluación económica de medicamentos y tecnologías sanitarias:

Resumen

La evaluación económica de medicamentos y tecnologías sanitarias es una disciplina relativamente nueva, donde confluyen metodologías llegadas de distintas áreas de conocimiento (medicina, farmacia, epidemiología, estadística, psicometría, economía, etc.). Por este motivo, durante un tiempo la metodología y las reglas empleadas en su elaboración y realización han sido un tanto heterogéneas y anárquícas, dado que cada investigador empleaba diferentes criterios y seguía distintas recomendaciones a la hora de diseñar, poner en marcha y analizar las evaluaciones económicas.

Cuanto más grandes somos en humildad, tanto más cerca estamos de la grandeza.

Rabindranath Tagore

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Rennie D, Luft HS. Pharmacoeconomic analysis. Making them transparent, making them credible. JAMA 2000; 283: 2158–2160.

    Google Scholar 

  2. Barnes R, Heaton A. Panel 6: addressing questions of bias, credibility, and quality in health economic evaluations. Value Health 1999; 2: 99–102.

    Google Scholar 

  3. Byford S, Palmer S. Common errors and controversies in pharmacoeconomic analyses. Pharmacoeconomics 1998; 13: 659–666.

    Google Scholar 

  4. Mullins CD, Ogilvie S. Emerging standardization in pharmacoeconomics. Clin Ther 1998; 20: 1194–1202.

    Google Scholar 

  5. Rovira J. Standardization of the economic evaluation of health technologies: European developments. Med Care 1996; 34 (Suppl1) DS13-DS22.

    Google Scholar 

  6. Siegel JE, Torrance GW, Russell LB, Luce BR, Weinstein MC, Glod MR. Guideline for pharmacoeconomics studies. Recommendation from the Panel on Cost-Effectiveness in Health and Medicine. Pharmacoeconomics 1997; 11: 159–168.

    Google Scholar 

  7. Jönsson B. Time for a common standard for cost-effectiveness in Europe? Eur J Health Econ 2006; 7: 223–224.

    Google Scholar 

  8. CADTH (Canadian Agency for Drugs and Technology in Health). Guidelines for the economic evaluation of health technologies, \(3_{\text{ rd }}\) Edition, 2006 ( http://www.cadth.ca)

  9. Jönsson B. Ten arguments for a societal perspective in the economic evaluation of medical innovations. Eur J Health Econ 2009; 10: 357–359.

    Google Scholar 

  10. Task Force on Principles for Economic Analysis of Healthcare Technology. Economic analysis of healthcare technology: a report on principles. Ann Intern Med 1995; 122: 61–70.

    Google Scholar 

  11. Song F, Altmen DG, Glenny A-M, Deeks JJ. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence for published meta-analyses. BMJ 2003; 326: 472.

    Google Scholar 

  12. Tappenden P, Chilcota J, Ward S, Eggington S, Hind D, Hummel S. Methodological issues in the economic analysis of cancer treatments. Eur J Cancer 2006; 42: 2867–2875.

    Google Scholar 

  13. McDonough CM, Tosteson ANA. Measuring preferences for cost-utility analysis. Pharmacoeconomics 2007; 25: 93–106.

    Google Scholar 

  14. Revicki DA, Frank L. Pharmacoeconomic evaluation in the real word. Pharmacoeconomics 1999; 15: 423–434.

    Google Scholar 

  15. Drummond M, Sculpher M. Common methodological flaws in economic evaluations. Med Care 2005; 43: ||5-||14.

    Google Scholar 

  16. Katz DA, Welch HG. Discounting in cost-effectiveness analysis of health care programmes. Pharmacoeconomics 1993; 3: 276–285.

    Google Scholar 

  17. Severens J, Milne RJ. Discounting health outcomes in economic evaluation: the ongoing debate. Value Health 2004; 7: 397–401.

    Google Scholar 

  18. Bos JM, Postme MJ, Annemans L. Discounting health effects in pharmacoeconomic evaluations: current controversies. Pharmacoeconomics 2005; 23: 639–649.

    Google Scholar 

  19. Graf von der Schulenburg JM, Hoffman C. Review of European guidelines for economic evaluation of medical technologies and pharmaceuticals. HEPAC 2000; 1: 2–8.

    Google Scholar 

  20. Weinstein MC, Siegel JE, Gold MR, Chalet MS, Russell LB, for the panel on cost-effectiveness in health and medicine. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA 1996; 276: 1253–1258.

    Google Scholar 

  21. Stinnett A, Mullahy J. Net health benefits: a new framework for the analysis of uncertainty in costeffectiveness analysis. Med Dec Making 1998; 18: S68–S80.

    Google Scholar 

  22. Trueman P, Drummond M, Hutton J. Developing guidance for budget impact analysis. Pharmacoeconomics 2001; 19: 609–621.

    Google Scholar 

  23. Briggs AH. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics 2000; 17: 479–500.

    Google Scholar 

  24. Fenwick L, Claxton K, Sculpher M. Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ 2002; 10: 779–789.

    Google Scholar 

  25. Sculpher M, Claxton K. Establishing the cost-effectiveness of new pharmaceuticals under conditions of uncertainty-when is there sufficient evidence? Value Health 2005; 8: 433–446.

    Google Scholar 

  26. Claxton K, Sculpher M. Using value of information analysis to prioritise health research. Some lessons from recent UK experience. Pharmacoeconomics 2006; 24: 1055–1068.

    Google Scholar 

  27. De Graeve D, Nonneman W. Pharmacoeconomic studies: pitfalls and problems. Int J Technol Assess Health Care 1996; 12: 22–30.

    Google Scholar 

  28. Klepser DG. Pitfalls associated with commonly used methods for pharmacoeconomics analyses. Pharmacotherapy 2002; 22(2 Pt 2): 35S–38S.

    Google Scholar 

  29. Sculpher MJ, Drummond MF. Analysis sans frontiers: can we ever make economic evaluations generalisable across jurisdictions? Pharmacoeconomics 2006; 24: 1087–1099.

    Google Scholar 

  30. International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Pharmacoeconomic guidelines around the world (www.ispor.org).

    Google Scholar 

  31. López Bastida J, Oliva J, Antoñanzas F, García-Altés A, Gisbert R, Mar J, et al. Propuesta de guía para la evaluación económica aplicada a las tecnologías sanitarias: una guía práctica. Gac Sanit 2010; 24: 209–214.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Freelance, C/ Arturo Soria 148, 1°-1°, Madrid, 28043, Madrid, Spain

    Javier Soto Álvarez

Authors
  1. Javier Soto Álvarez
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Javier Soto Álvarez .

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Healthcare Iberica, S.L.

About this chapter

Cite this chapter

Soto Álvarez, J. (2012). Estandarización en el diseño y realización de evaluaciones económicas: recomendaciones y guías existentes. In: Evaluación económica de medicamentos y tecnologías sanitarias:. Springer Healthcare, Madrid. https://doi.org/10.1007/978-84-940346-6-4_2

Download citation

  • DOI: https://doi.org/10.1007/978-84-940346-6-4_2

  • Published:

  • Publisher Name: Springer Healthcare, Madrid

  • Print ISBN: 978-84-940346-1-9

  • Online ISBN: 978-84-940346-6-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation